Paper Details

  1. Home
  2. Paper Details

Treatment of pulmonary tuberculosis with short course chemotherapy in south India--5-year follow up.

Author: BalasubramanianR, JanardhanamB, KrishnamurthyM S, NazarethO, PrabhakarR, SanthaT, TripathyS P, VenkataramanP, VijayanV K

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study compared three short-course chemotherapy regimens for treating tuberculosis. The regimens included different combinations of rifampicin, streptomycin, isoniazid, and pyrazinamide, with varying durations of treatment. The relapse rate within 5 years was similar across all three regimens, ranging from 4.0% to 7.1%. Most relapses occurred within the first two years after treatment completion. The study also found that patients with initial drug resistance had a higher relapse rate, with 6 relapses occurring in a group of 65 patients with resistance to streptomycin or isoniazid.
Paper Details　
Original Abstract of the Article :
A controlled clinical trial of three short-course chemotherapy regimens was undertaken in patients with newly diagnosed bacteriologically positive pulmonary tuberculosis. The patients were randomly allocated to receive one of three regimens: rifampicin, streptomycin, isoniazid and pyrazinamide daily...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0041-3879(89)90016-0

データ提供：米国国立医学図書館（NLM）

Short-Course Chemotherapy for Pulmonary Tuberculosis

Pulmonary tuberculosis, a persistent threat to global health, is like a stubborn desert sandstorm that can be difficult to control. This research investigates the effectiveness of different short-course chemotherapy regimens in treating tuberculosis. The study highlights the need for long-term follow-up to assess the efficacy and potential risks of treatment options. It's like navigating a treacherous desert landscape, where the path to recovery is fraught with challenges and requires constant vigilance.

Finding the Right Path in the Tuberculosis Desert

The study revealed that all three short-course chemotherapy regimens demonstrated comparable efficacy in treating tuberculosis, with a relapse rate of around 5% after 5 years. It's like finding a network of paths through the desert, each offering a viable route to reaching the oasis of recovery.

Navigating the Treatment Landscape

The study highlights the importance of long-term follow-up in managing tuberculosis. It's a reminder that even though we might find a path through the desert, we need to ensure its stability and monitor for potential pitfalls along the way.

Dr.Camel's Conclusion

This research provides valuable insights into the management of tuberculosis, a disease that has plagued humanity for centuries. It's like a mapmaker charting a new course through the desert, offering hope for those struggling with this persistent threat. The study emphasizes the importance of continued research and careful monitoring to ensure the most effective and safe treatment strategies.

Date :
  1. Date Completed 1990-04-11
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

2516669

DOI: Digital Object Identifier

10.1016/0041-3879(89)90016-0

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.